Search
for
Sort by
Research 31–60 of 1000+
- Deficiency in alopecia areata and responsiveness to vitamin D analogues: A prospective trial
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study
- Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital
- Case Report: Dupilumab induced sustained complete remission in a child with severe alopecia areata and markedly elevated IgE
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort
- Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
- Upadacitinib for the treatment of alopecia areata – A case report
- Two‐dimensional planimetry for alopecia areata severity evaluation compared with severity of alopecia tool: A pilot study
- Serum level of retinol-binding protein 4 in alopecia areata: relation with recurrence and severity
- Evaluation of vitamin D in pediatric alopecia areata: A case–control study of thirty patients in a tertiary care hospital
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
- Comparison of Trichoscopic Features of Alopecia Areata before and after Treatment with Intralesional Steroids
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- Tofacitinib for the treatment of alopecia areata and variants in adolescents
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- Alopecia areata: An update
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis